ArticleAnnals of Ibadan postgraduate medicine2021
NF-KB A KEY TRANSCRIPTION FACTOR IN DISEASE PROGRESSION OF PATIENTS WITH COVID-19.
Article in Annals of Ibadan postgraduate medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Association of TLR8 Variants in Sex-Based Clinical Differences in Patients with COVID-19.Biochemical genetics · 2025Article
- Highlights on molecular targets in the management of COVID-19: Possible role of pharmacogenomics.The Journal of international medical research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Covid19 is a current pandemic caused by SARS COVID2 virus. It is a RNA virus consists of outer spike glycoproteins. These PAMP's such as surface glycoproteins were recognized by PRR (pattern recognition receptors) belongs to TLR's especially TLR7 and TLR8 on immune cells activate NF-KB a key transcription factor involved in development of immunity. Dysregulated NF-KB a key transcription factor activates inflammatory mediators involved in disease progression in COVID patients. Targeting NF-KB, a key transcription factor and suppressing it, helps in suppressing the progression of disease for better prognosis. This article highlights about the NF-KB, a key transcription factor activity in progression of diseases in COVID19 patients, which is helpful for future therapeutic target and prognostic marker.
Indexed as
Identifiers
35095375PMC8791396W4210822024What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.